Abstract:Enterovirus A71 (EV-A71) infection is a major cause of severe hand, foot and mouth disease (HFMD) in young children. The characteristics of EV-A71 neutralizing antibodies in HFMD patients are not well understood. In this study, we identified and cloned EV-A71-neutralizing antibodies by single cell RNA and B cell receptor sequencing of peripheral blood mononuclear cells. From 145 plasmablasts, we identified two IgG1 monoclonal antibodies (mAbs) and six IgM mAbs that neutralized EV-A71. Four of the IgM mAbs harbor germline variable sequences and neutralize EV-A71 potently. Two genetically similar IgM antibodies from two patients have recurrent heavy chain variable domain gene usage and similar complementarity-determining region 3 sequences. We mapped the residues of EV-A71 critical for neutralization through selection of virus variants resistant to antibody neutralization in the presence of neutralizing mAbs. The residues critical for neutralization are conserved among EV-A71 genotypes. Epitopes for the two genetically similar antibodies overlap with the SCARB2 binding site of EV-A71. We used escape variants to measure the epitope-specific antibody response in acute phase serum samples from EV-A71 infected HFMD patients. We found that these epitopes are immunogenic and contributed to the neutralizing antibody response against the virus. Our findings advance understanding of antibody response to EV-A71 infection in young children and have translational potential: the IgM mAbs could potentially be used for prevention or treatment of EV-A71 infections. Hand, foot and mouth disease (HFMD) caused by enterovirus infections affects millions of young children annually. Enterovirus A71 (EV-A71) is a major causative pathogen of severe HFMD. EV-A71-specific antibody response is induced rapidly after illness onset, but the characteristics of primary antibody response to EV-A71 in young children are not well understood. Previous study demonstrated a dominant IgM producing EV-A71-specific antibody-secreting B cell response in children under 3 years old. However, no EV-A71-specific human IgM mAb has been reported. Here, we identified EV-A71 neutralizing mAbs, including two IgG1 and six IgM mAbs, from plasmablasts of EV-A71 infected children. IgM mAbs neutralize EV-A71 potently although possess few somatic mutations. We found sequence similarities between IgM antibodies from two patients. We selected EV-A71 variants in the presence of neutralizing mAbs and demonstrated that residues critical for neutralization are conserved among EV-A71 genotypes. We further explored epitope specific antibody responses in acute phase sera of EV-A71 infected patients and found that these neutralizing epitopes on the virus are immunogenic. Our findings advance understanding of antibody response in EV-A71 infected HFMD patients and can help inform the development of therapies against EV-A71 infections.

Preparation and verification of a monoclonal antibody against a conserved linear epitope in enterovirus A protein 2C

Identification of a Conserved, Linear Epitope on VP3 of Enterovirus A Species Recognized by a Broad-Spectrum Monoclonal Antibody

Structural and functional analysis of a potent human neutralizing antibody against enterovirus A71

[Preparation of monoclonal antibody against enterovirus 71 capsid protein VP1].

[Preparation of monoclonal antibodies against enterovirus type 71 with an epitope-incorporated adenovirus type 3 vector].

Structural Basis for Recognition of Human Enterovirus 71 by a Bivalent Broadly Neutralizing Monoclonal Antibody

Generation and Characterization of a Protective Mouse Monoclonal Antibody Against Human Enterovirus 71

Antibody signatures in hospitalized hand, foot and mouth disease patients with acute enterovirus A71 infection

Protection against lethal enterovirus 71 challenge in mice by a recombinant vaccine candidate containing a broadly cross-neutralizing epitope within the VP2 EF loop.

Generation of neutralizing monoclonal antibodies against Enterovirus 71 using synthetic peptides

In Vivo Time-Related Evaluation of a Therapeutic Neutralization Monoclonal Antibody Against Lethal Enterovirus 71 Infection in a Mouse Model.

Preparation and characterization of enterovirus 71 VP1 monoclonal antibody

Preparation and Identification of Monoclonal Antibody Against Cytolysin of Vibrio Vulnificus

Single Neutralizing Monoclonal Antibodies Targeting the VP1 GH Loop of Enterovirus 71 Inhibit both Virus Attachment and Internalization during Viral Entry

Dual blockages of a broad and potent neutralizing IgM antibody targeting GH loop of EV-As

Serotype specific epitopes identified by neutralizing antibodies underpin immunogenic differences in Enterovirus B

Enterovirus 71 viral capsid protein linear epitopes: Identification and characterization

A bispecific broadly neutralizing antibody against enterovirus 71 and coxsackievirus A16 with therapeutic potential.

Immunoreactivity Analysis of the Nonstructural Proteins of Human Enterovirus 71.

Identification of specific antigenic epitope at N-terminal segment of enterovirus 71 (EV-71) VP1 protein and characterization of its use in recombinant form for early diagnosis of EV-71 infection

Crystal Structures of Yeast-Produced Enterovirus 71 and Enterovirus 71/Coxsackievirus A16 Chimeric Virus-Like Particles Provide the Structural Basis for Novel Vaccine Design against Hand-Foot-and-Mouth Disease